Scienture Holdings Inc. (NASDAQ:SCNX) on Monday reported fourth-quarter financial performance, with net revenue increase of 216% to $431.6 thousand. The revenue was driven by initial sales of Arbli following its FDA approval and commercial launch in the third quarter of 2025.

Margin Expansion

Gross margin expanded significantly by 7,240 basis points to 76.8%, reflecting the transition to higher-margin branded pharmaceutical sales from prior lower-margin wholesale activity.

Excluding a one-time, non-cash impairment charge of $26.3 million, net loss from continuing operations narrowed modestly year-over-year.

Scienture ended the year with approximately $6.7 million in cash and cash equivalents, alongside positive working capital of about $5.2 million.

Commercial Expansion For Arbli

During the year, Scienture secured multiple pharmacy benefit manager-led group purchasing organization rebate agreements, boosting formulary positioning and commercial coverage for Arbli.

The company also executed institutional group purchasing agreements, expanding access to more than 2,500 healthcare institutions across the U.S.

Arbli achieved formulary inclusion with major national health plans, extending coverage to over 100 million lives.

Patent Wins Strengthen Scienture Portfolio

Scienture received an Orange Book-listable patent for Arbli (losartan potassium) oral suspension, 10mg/mL. The product is the first FDA-approved ready-to-use oral liquid losartan in the U.S. for hypertension treatment.

The company also secured an Orange Book-listed patent for REZENOPY (naloxone HCl) nasal spray 10 mg, currently the highest-dose FDA-approved naloxone nasal spray for emergency opioid overdose treatment.

Strategic Partnerships And Broader Access

Scienture established a strategic collaboration with BlinkRx to enhance patient access and adherence for Arbli through integrated digital pharmacy services.

Additionally, the company formalized multiple commercial group purchasing agreements for REZENOPY, expanding access to more than 5,000 healthcare institutions and reaching roughly 60% of the U.S. institutional market, including first responders and rehabilitation centers.

Management Commentary

Narasimhan Mani, President and Co-CEO of Scienture, commented, “2025 was a transformational year for Scienture.

“We believe 2026 will reflect the momentum we’ve built across prescriber adoption, distribution, and patient demand for Arbli, while also positioning us for the planned commercial launch of REZENOPY in the second quarter of 2026,” stated Shankar Hariharan, Executive Chairman and co-CEO of Scienture.

SCNX Stock Price Activity: Scienture shares were up 1.44% at $0.423 during premarket trading on Monday, according to Benzinga Pro data.

Image via Shutterstock